Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers.
CAR-T therapy is a revolutionary new treatment option that uses a patient’s immune system to fight their cancer.
Carina is developing CAR-T and other adoptive cell therapies that can be used to treat solid cancers, are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing.
Learn more about CAR-T therapy